PAPER Guo X, Williams JG, Schug TT, Li X
SEARCH RESULTS
331007 RESULTS
PAPER Wang H, Zhang W, Tang R, Zhu C, Bucher C, Blazar BR, Geng JG, Zhang C, Linden J, Wu C, Huo Y
Adenosine receptor A2A deficiency in leukocytes increases arterial neointima formation in apolipoprotein E-deficient mice.
Arterioscler Thromb Vasc Biol. 2010 May;30(5):915-22. PubMed: 20167656PAPER Stratmann G, Sall JW, Bell JS, Alvi RS, May LV, Ku B, Dowlatshahi M, Dai R, Bickler PE, Russell I, Lee MT, Hrubos MW, Chiu C
Isoflurane does not affect brain cell death, hippocampal neurogenesis, or long-term neurocognitive outcome in aged rats.
Anesthesiology. 2010 Feb;112(2):305-15. PubMed: 20098132PAPER Homsi S, Piaggio T, Croci N, Noble F, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M
Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study.
J Neurotrauma. 2010 May;27(5):911-21. PubMed: 20166806PAPER Li L, Willets RS, Polidori MC, Stahl W, Nelles G, Sies H, Griffiths HR
Oxidative LDL modification is increased in vascular dementia and is inversely associated with cognitive performance.
Free Radic Res. 2010 Mar;44(3):241-8. PubMed: 20166891PAPER Chakraborti AK, Garg SK, Kumar R, Motiwala HF, Jadhavar PS
Progress in COX-2 inhibitors: a journey so far.
Curr Med Chem. 2010;17(15):1563-93. PubMed: 20166930PAPER Rossé G, Schaffhauser H
5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.
Curr Top Med Chem. 2010;10(2):207-21. PubMed: 20166958PAPER Haydar SN, Dunlop J
Neuronal nicotinic acetylcholine receptors- targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.
Curr Top Med Chem. 2010;10(2):144-52. PubMed: 20166959PAPER Sajjad MU, Samson B, Wyttenbach A
Heat shock proteins: therapeutic drug targets for chronic neurodegeneration?
Curr Pharm Biotechnol. 2010 Feb;11(2):198-215. PubMed: 20166961PAPER Nagai Y, Fujikake N, Popiel HA, Wada K
Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
Curr Pharm Biotechnol. 2010 Feb;11(2):188-97. PubMed: 20166962PAPER Luo GR, Le WD
Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.
Curr Pharm Biotechnol. 2010 Feb;11(2):180-7. PubMed: 20166963PAPER Laskowska E, Matuszewska E, Kuczyńska-Wiśnik D
Small heat shock proteins and protein-misfolding diseases.
Curr Pharm Biotechnol. 2010 Feb;11(2):146-57. PubMed: 20166966PAPER Correia SC, Santos RX, Cardoso S, Carvalho C, Santos MS, Oliveira CR, Moreira PI
Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer's disease?
Curr Aging Sci. 2010 Jul;3(2):113-26. PubMed: 20167003PAPER Randall AD, Witton J, Booth C, Hynes-Allen A, Brown JT
The functional neurophysiology of the amyloid precursor protein (APP) processing pathway.
Neuropharmacology. 2010 Sep-Oct;59(4-5):243-67. PubMed: 20167227PAPER Geppert AM, Losy J, Przedpelska-Ober E, Kozubski W
CCL3 correlates with the number of mood disturbances and personality changes in patients with Alzheimer's disease.
Psychiatry Res. 2010 Apr 30;176(2-3):261-4. PubMed: 20167378Current Filters
No filters selected